Adintrevimab for COVID-19: real-time analysis of 3 studies

Download Image

Post

c19early.org

Adintrevimab for COVID-19

2 studies with >2,000 patients

Serious outcome risk

Adintrevimab

Control

Significantly lower risk for hospitalization and cases.

2 studies (both from the same team/sponsor) show significant benefit.

COVID-19 Adintrevimab studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (2)43%

Mortality (2)43%

Hospitalization (2)83%

Cases (2)71%

RCTs (2)43%

RCT mortality (2)43%

Prophylaxis (2)43%

00.511.5+

← Adintrevimab
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

mAb use may create new variants that spread globally1-3, and may be associated with increased risk of autoimmune disease4, prolonged viral loads, clinical deterioration, and immune escape2,5-9.


	Covid Analysis	Adintrevimab for COVID-19: real-time meta-analysis of 2 studies
	Significantly lower risk is seen for hospitalization and cases. 2 studies (both from the same team/sponsor) show significant benefit. Meta-analysis using the most serious outcome reported shows 43% [-169‑88%] lower risk, withou..
Aug 11 2024	Focosi, D., Current Topics in Microbiology and Immunology, doi:10.1007/82_2024_268	Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities
	Review of monoclonal antibodies for SARS-CoV-2. Author notes that the omicron variant has reset achievements to date.
Aug 8 2024	Casadevall et al., Clinical Infectious Diseases, doi:10.1093/cid/ciae408	Single monoclonal antibodies should not be used for COVID-19 therapy: a call for antiviral stewardship
	Review arguing against use of single monoclonal antibodies for COVID-19 treatment, particularly in immunosuppressed patients, due to the risk of rapidly selecting for resistant viral variants. Authors suggest that while monoclonal antibod..
Jun 13 2023	Ison et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofad314	Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)
	75% fewer symptomatic cases (p=0.03). PEP RCT 351 patients, showing lower COVID-19 cases with adintrevimab. The PrEP trial is listed separately [Ison].
Jun 13 2023	Ison et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofad314	Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)
	84% lower hospitalization (p=0.07) and 70% fewer symptomatic cases (p<0.0001). PrEP RCT 1480 patients, showing lower COVID-19 cases with adintrevimab. The PEP trial is listed separately [Ison].
Jan 24 2023	Zumbrun et al., Antimicrobial Agents and Chemotherapy, doi:10.1128/aac.01353-22	Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19
	Hamster and monkey study showing dose-dependent protection against SARS-CoV-2 infection with prophylactic administration of a single dose of adintrevimab.